Dermatol. praxi. 2012;6(2):87-89

Photoallergic dermatitis induced by fenofibrate

MUDr.Jan Šternberský, MUDr.Iva Karlová
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Photoallergic dermatitis is characterized by qualitatively altered skin sensitivity to sunlight. This alteration occurs as a result of a mutual

interaction between sunlight and a specific photoallergen following an individual's previous sensitization. A photoallergen enters the body

through contact with the skin, orally, or parenterally, and causes photosensitization. During exposure, a skin reaction characterized by erythematous

plaques, not uncommonly with an eruption of papulovesicles, occurs in areas of the skin exposed to light. The paper presents a

case of a 68-year-old female patient who developed photoallergic dermatitis due to a newly introduced treatment with fenofibrate.

Keywords: photoallergic dermatitis, fenofibrate, allergic cross-reaction, photoepicutaneous testing

Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šternberský J, Karlová I. Photoallergic dermatitis induced by fenofibrate. Dermatol. praxi. 2012;6(2):87-89.
Download citation

References

  1. Kerr A, Ferguson J. Photoallergic contact dermatitis. Photodermatology, Photoimmunology & Photomedicine 2010; 26(Issue 2): 56-65. Go to original source... Go to PubMed...
  2. Burgdorf WHC, Plewig G, Wolff HH, Landthaler M. BraunFalco's Dermatology. 3rd edition. Springer, 2009: 1712p. Go to original source...
  3. Štork J, et al. Dermatovenerologie. Galén 2008: 502p.
  4. Rietschel RL, Fowler jr JF. Fischer's Contact Dermatitis 5th Edition. Lippincott Williams & Wilkins 2001: 862p.
  5. Batchelor RJ, Wilkinson SM. Photopatch testing - a retrospective review using the 1 day and 2 day irradiation protocols. Contact Dermatitis 2006; 54(Issue 2): 75-78. Go to original source... Go to PubMed...
  6. Dastychová E. Nežádoucí účinky extern obsahujících ketoprofen. Čes-slov. Derm. 2000; 75(No. 2): 51-55. 6. 2-Hydroxy-4-methoxybenzo-phenone (Benzophenone-3) 10,0% vaz.
  7. 6-Methyl coumarine (6-MC) 1,0% vaz.
  8. Bithionol 1,0% vaz.
  9. Fentichlor (2,2'-Thiobis(4-chlorophenol)) 1,0% vaz.
  10. (+)-Usnic acid 0,1% vaz.
  11. Atranorin 0,1% vaz.
  12. Směs dřevin (borovice, smrk, bříza, teak) 20,0% vaz.
  13. Evernic acid 0,1% vaz.
  14. Balsam Peru (Myroxylon pereirae) (sorb. Sesquinol. 5) 25,0% vaz.
  15. 3,3', 4', 5-Tetrachloro salicylanilide (TCS) 0,1% vaz.
  16. Hexachlorophene 1,0% vaz.
  17. Chlorhexidine digluconate 0,5% aq.
  18. Triclosan (Irgasan DP 300) 2,0% vaz.
  19. Diphenhydramine hydrochloride 1,0% vaz.
  20. Směs parfémů 6,0% vaz.




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.